Disease Domain | Count |
---|---|
Infectious Diseases | 3 |
Endocrinology and Metabolic Disease | 1 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Prophylactic vaccine | 2 |
Target |
Mechanism TGF-β1 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TGF-β1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TLR2 antagonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date06 May 2024 |
Sponsor / Collaborator |
Start Date15 Apr 2024 |
Sponsor / Collaborator |
Start Date01 Apr 2024 |
Sponsor / Collaborator ![]() [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Fluorofenidone ( TGF-β1 x p38γ ) | Liver Cirrhosis More | Phase 2 |
Mefunidone Hydrochloride ( TGF-β1 ) | Type 2 diabetes mellitus with established diabetic nephropathy More | Phase 2 |
MPXV-2 ( TLR2 x TLR4 ) | Virus Diseases More | Preclinical |
MPXV-5 ( TLR2 x TLR4 ) | Virus Diseases More | Preclinical |
D-6808 ( c-Met ) | Stomach Cancer More | Discovery |